Evaluation of Multi-Cancer Early Detection Testing in a High-Risk Population: The INFORM Study
NCT06450171
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this research study is to evaluate the possible benefits and harms of screening with an investigational blood test designed to detect many types of cancer early. The name of the screening blood test being studied is: -GRAIL Galleri test
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cancer Predisposition Syndrome
- Predisposition, Genetic
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 22 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Dana-Farber Cancer Institute
- Last updated on ClinicalTrials.gov
- January 20, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Massachusetts · 1
- Dana-Farber Cancer Institute · Boston, MA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.